StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) company profile

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

About Summit Therapeutics

Pharmaceutical Preparations, SIC 2834

Summit Therapeutics Inc. is a biopharmaceutical company engaged in discovering, developing, and commercializing medicinal therapies in the oncology sector. Its principal lead investigational candidate is ivonescimab, a bispecific antibody designed to combine anti-angiogenesis and immunotherapy targeting VEGF and PD-1 pathways. The company focuses on developing treatments for patients with solid tumor malignancies, primarily evaluating clinical indications in non-small cell lung cancer and colorectal cancer.

The company holds licensed development and commercial rights for ivonescimab across multiple geographic territories, encompassing the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Its clinical trial programs operate across multiregional sites, including study locations in North America and Europe alongside partner-run trials in China. Over 4,000 trial participants have received ivonescimab globally. The provided excerpt does not identify the company's specific headquarters location.

Summary of the business section of Summit Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Summit Therapeutics Inc.
Headquarters
Miami, FL
Address
601 Brickell Key Drive, Suite 1000 33131
Phone
(305) 203-2034
Website
smmttx.com
Employees
265, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
SMMT
Exchange
Nasdaq
IPO date
Mar 5, 2015
Shares outstanding
798M, Jul 17, 2026
Public float
$2.48B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-5 reverse, Sep 18, 2020
SEC CIK
1599298
CUSIP
86627T108
ISIN
US86627T1088
FIGI
BBG00X3GQL76
Share class FIGI
BBG00X3GQL94
EIN
37-1979717

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mahkam ZanganehCo-Chief Executive Officer, Director610,515,809
Robert W. DugganCo-Chief Executive Officer, Director610,515,809
Manmeet Singh SoniCOO and CFO, Director3,224,375
Bhaskar AnandChief Accounting Officer261,047
Jeff HuberDirector50,052
Mostafa RonaghiDirector–
Kenneth A. ClarkDirector–
Robert F. BoothDirector–
Yu XiaDirector32,057,147
Alessandra CesanoDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Duggan
$172.38K$172.38K$249.13M$372$120
FY2025
Zanganeh
$246.05M$233.11M$249.13M$372$120
FY2024
Duggan
$158.61K$158.61K$2.51M$380$114
FY2024
Zanganeh
$1.16M$228.31M$2.51M$380$114
FY2023$20.56M$30.06M$12.05M$56$116
FY2022$1.24M$3.79M$1.36M$90$112

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 5, 2015
Offer price
$9.90
Securities offered
3,450,000
Gross proceeds
$34.16M
Exchange
Nasdaq
First trading day
Mar 5, 2015
First-day close
$2.04-79.4%
Lock-up ends (est.)
Sep 1, 2015

“The initial public offering price is $9.90 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 265 total employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 6, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 26, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 18, 2020DelistingNotice of delisting from exchange (Form 25)
Sep 17, 2020Name changeName changed from Summit Therapeutics plc to Summit Therapeutics Inc.
Mar 5, 2015IPOInitial public offering priced (424B4 prospectus)
Mar 2, 2015ListingRegistration of securities on an exchange (Form 8-A)
Jan 30, 2015Name changeName changed from Summit Corp plc to Summit Therapeutics plc

See a number that looks wrong?